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Abstract
While smoking is the primary cause of lung cancer, only 11–24% of smokers develop the
malignancy over their lifetime. The primary addictive agent in tobacco smoke is nicotine and
variation in nicotine metabolism may influence the smoking levels of an individual. There-
fore, inter-individual variation in lung cancer risk among smokers may be due in part to
differences in the activity of enzymes involved in nicotine metabolism. In most smokers,
cytochrome P450 2A6 (CYP2A6)-catalyzed C-oxidation accounts for >75% of nicotine
metabolism, and the activity of this enzyme has been shown to correlate with the amount of
nicotine and carcinogens drawn from cigarettes. We prospectively evaluated the association
of urinary biomarkers of nicotine uptake (total nicotine equivalents [TNE]) and CYP2A6
activity (ratio of urinary total trans-30-hydroxycotinine to cotinine) with lung cancer risk
among 2,309 Multiethnic Cohort Study participants who were current smokers at time of
urine collection; 92 cases were diagnosed during a mean follow-up of 9.5 years. We found
that higher CYP2A6 activity and TNE was associated with increased lung cancer risk after
adjusting for age, sex, race/ethnicity, body mass index, smoking duration, and urinary creati-
nine (p’s = 0.002). The association for CYP2A6 activity remained even after adjusting for
self-reported cigarettes per day (CPD) (Hazard Ratio [HR] per unit increase in log-CYP2A6
activity = 1.52; p = 0.005) and after adjusting for TNE (HR = 1.46; p = 0.01). In contrast, the
association between TNE and lung cancer risk was of borderline statistical significance
when adjusted for CPD (HR = 1.53; p = 0.06) and not statistically significant when further
adjusted for CYP2A6 activity (HR = 1.30; p = 0.22). These findings suggest that CYP2A6
activity provides information on lung cancer risk that is not captured by smoking history or a
(short-term) biomarker of dose. CYP2A6 activity should be further studied as a risk bio-
marker for smoking-related lung cancer.
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Introduction
Lung cancer is the second most common cancer in men and women, and the most common
cause of cancer death [1]. Approximately 90% of lung cancer cases in the United States can be
attributed to tobacco smoking [2]. However, only 11–24% of smokers will develop lung cancer
over their lifetimes [2], and for the same self-reported number of cigarettes per day (CPD),
lung cancer risk differs across racial/ethnic groups [3]. Nicotine is the primary addictive agent
in tobacco smoke and these differences in risk have been suggested to be in part due to genetic
variation in nicotine metabolism [4].
In most smokers, cytochrome P450 2A6 (CYP2A6)–catalyzed C-oxidation accounts for
>75% of nicotine’s metabolism [5, 6]. The product of this pathway, cotinine, is then converted
by CYP2A6, to trans-30-hydroxycotinine (3-HCOT). Quantifying the sum of 3-HCOT and its
glucuronide conjugate (referred to as "total 3-HCOT") captures the total conversion of cotin-
ine to 3-HCOT. The ratio of total 3-HCOT to cotinine is a measure of CYP2A6 activity [5],
which has been shown to influence smoking intensity [7, 8]. Smokers with reduced CYP2A6
activity tend to smoke less intensively, drawing in lower doses of nicotine and carcinogens
from each cigarette, than do smokers with higher CYP2A6 activity because the former have
more residual nicotine in their systems [7–10]. The dose of nicotine inhaled by a smoker may
be quantified by measuring urinary total nicotine equivalents (TNE), which is the sum of total
nicotine, total cotinine, total 3-HCOT and nicotine N-oxide. "Total” refers to the sum of the
compound and its glucuronide conjugate. TNE is an excellent biomarker of short-term inter-
nal smoking dose since it captures 85–90% of nicotine uptake [5, 6]. A recent publication from
the Shanghai Men’s Health study reported that CYP2A6 genetic variants confirmed to be asso-
ciated with a reduced enzymatic activity were associated with a decreased risk of lung cancer
(odds ratio [OR] = 0.64; p = 0.03) [11]. This association was no longer statistically significant
after accounting for TNE (OR = 0.74; p = 0.18), suggesting that the observed genetic associa-
tion with lung cancer was the result of the relationship between nicotine metabolism and
smoking dose.
The majority of studies that have been conducted have found that CYP2A6 variants that
result in reduced or no enzymatic activity are inversely associated with lung cancer risk [11–
19]. However, many of these variants are specific to some populations (e.g. 4 is common in
Japanese but rare in whites) and these genetic polymorphisms explain only a fraction of the
variation in CYP2A6 activity (~44–64% depending on the ethnic/racial group) [9]; therefore,
the phenotypic biomarker for CYP2A6 activity is expected to constitute a more suitable pre-
dictor of lung cancer risk. However, to date, there is no published data prospectively evaluating
the association of a biomarker of nicotine metabolism with lung cancer risk. To determine
whether such a biomarker captures information on lung cancer risk in current smokers
beyond that provided by self-reported smoking history and internal smoking dose, we pro-
spectively examined the association of a urinary biomarker of CYP2A6 activity with lung can-
cer risk among smokers in the Multiethnic Cohort (MEC) study.
Materials and methods
Study population
Subjects were participants in the MEC study, a prospective cohort study investigating the asso-
ciation of lifestyle and genetic factors with chronic diseases in five ethnic/racial populations
(African Americans, Japanese Americans, Latinos, Native Hawaiians, and Whites) from
Hawaii and Los Angeles, California [20]. This study comprised 215,251 men and women
between the ages of 45 and 75 years at time of recruitment. In 1993–1996, each participant
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completed a mailed, self-administered questionnaire regarding demographic, dietary and
other lifestyle exposures. The questions used in this study have undergone rigorous pilot test-
ing and have been validated in a multiethnic test population at the time of design of the MEC
study [20]. Briefly, pre-testing activities began with face-to-face administration of early drafts
by trained interviewers. After revisions to improve awkward wording and layout, a mailed
questionnaire was distributed to 130 subjects and later expanded to 1,000 randomly selected
subjects of each racial/ethnic group. Reproducibility of the questionnaire was tested approxi-
mately 6 months later in about 300 subjects. Specifically, in relation to smoking, we found that
the gold standard biomarker for internal smoking dose, total nicotine equivalents (which
accounts for>85% of nicotine uptake), was significantly correlated with self-reported smoking
dose, cigarettes per day (partial correlation, adjusted for age, sex, and race/ethnicity r = 0.50).
Approximately 10 years after baseline, a blood sample and an overnight (in Hawaii) or first
morning (in Los Angeles) urine sample were collected from over 67,000 MEC participants. A
short questionnaire was administered to update cigarette smoking exposure during the previ-
ous two weeks. All urine was kept on ice until processing. Aliquots were subsequently stored at
-80˚C until analysis. Approval for this study, including the consent procedure, was obtained
from the Institutional Review Boards of the University of Minnesota, the University of Hawaii,
and the University of Southern California. Study participants provided written consent.
IRB Code Number: 0912M75654. The present study includes 2,384 participants in the Bios-
pecimen subcohort who were lung cancer-free and current smokers at the time of sample col-
lection [6]. Baseline characteristics of participants, such as the average number of CPD and
smoking duration were similar to those of the entire MEC population within each sex and
racial/ethnic group [20].
Epidemiologic data
The epidemiologic data used in this analysis, including information on smoking history, was
obtained from a questionnaire administered at time of urine collection. Smoking duration and
intensity at time of urine collection was collected using the following respective questions:
“what is the total number of years you smoked” and “what is the average number of cigarettes
smoked per day for the past two weeks” (prior to the date of urine collection). The data from
the self-administered baseline and 10-year follow-up questionnaires were also used to impute
body mass index (BMI) and CPD when missing at time of urine collection or to compute
smoking duration [6]. Only one participant had no smoking duration information in the data-
base and was excluded from the analysis.
Biomarkers of smoking dose and nicotine metabolism
TNE was quantified as the sum of the urinary concentrations of total nicotine, total cotinine,
and total 3-HCOT and nicotine N-oxide, where “total” refers to the sum of the metabolite and
its glucuronide conjugate. CYP2A6 enzymatic activity was quantified as the ratio of total
3-HCOT/cotinine. All biomarkers were measured in all MEC smokers who provided a urine
sample using liquid chromatography tandem mass spectrometry on urine samples [6]. The
coefficient of variation for 22 undiluted samples from 10 blind replicates provided with the
MEC samples was: 9.9% for TNE and 8.2% for total 3-HCOT/cotinine. Because there are large
differences in creatinine levels by urine collection method (overnight in Hawaii vs. first morn-
ing in Los Angeles) and across the racial/ethnic groups, TNE was expressed in nmol/ml as
opposed to per mg of creatinine and the creatinine values were adjusted for in the multivari-
able model.
CYP2A6 activity associated with lung cancer
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Follow-up and case ascertainment
To evaluate the risk of lung cancer in current smokers, this study encompassed the full range
of TNE and CYP2A6 activity by including all MEC current smokers who were part of the Bios-
pecimen subcohort. TNE was used to confirm current smoking status. Subjects with TNE
>1.27 nmol/ml (4-times the limit of quantitation) were excluded, as this would indicate that
these participants were not current smokers at the time of urine collection. For this study, we
only included subjects who had complete data for the main covariates: age, sex, race/ethnicity,
CPD and smoking duration. This resulted in n = 2,309 eligible participants. Participants’ fol-
low-up began at the time of urine collection, for which urinary biomarkers of CYP2A6 activity
and TNE were measured, and continued until the first of the following endpoints: 1) diagnosis
of lung cancer; 2) death; or 3) end of follow-up, December 31, 2012 for participants in Los
Angeles or December 31, 2014 for participants in Hawaii. Incident cancer cases, defined by
International Classification of Diseases for oncology (ICD-O-3) and ICD-10, C34, were identi-
fied through linkages of the cohort to the Hawaii and California tumor registries which are
part of the Surveillance, Epidemiology and End Results (SEER) program of NCI. Deaths are
identified through annual linkage to state death certificate files in California and Hawaii and
periodically to the National Death Index. By the end of follow-up (average 9.5 years), 92 inci-
dent invasive primary lung cancer cases were identified. Among the lung cancer cases, the
majority were diagnosed with distant stage (53%); squamous cell carcinoma and adenocarci-
noma were the most common histological cell-types (31% and 29%, respectively), followed by
other/unspecified (21%), small cell lung cancer (15%) and large cell lung cancer (4%). Missing
information on stage (n = 24) and histology (n = 8) and the unspecified cell-types (n = 18)
were the results of these cases being identified by the rapid reporting system of the SEER regis-
tries which does not immediately capture all relevant information.
Statistical methods
Risk of lung cancer was estimated by the hazard ratios (HR) and 95% confidence intervals
(CIs) using Cox proportional hazards models where age was the time metric and follow-up
began at urine collection. To reduce the influence of outliers on the results, we log-trans-
formed (natural log) the variables with long right hand tails: BMI, CPD, creatinine, CYP2A6
activity and TNE. Distribution plots for CYP2A6 activity and TNE can be found in Supple-
mental Materials. Analyses were adjusted for age at urine collection (years, continuous), sex,
race/ethnicity, urinary log-creatinine, log-BMI, and smoking duration (years, continuous)
(Model 1). To investigate potential residual confounding by racial admixture within this multi-
ethnic population, the analysis was also carried out on a subset of 2,215 smokers with GWAS
data [21] using a model adjusted for principal components of genetic ancestry [22]; findings
were similar. To assess whether the biomarkers of nicotine uptake provided information on
lung cancer risk beyond that provided by self-reported measures of smoking, Model 1 was fur-
ther adjusted for self-reported CPD (Model 2). Finally, to assess independent effects of these
biomarkers, as CYP2A6 activity has been found to influence smoking behavior [10] and dose
[7, 8, 10], we adjusted the model for both biomarkers of CYP2A6 activity and smoking dose
(Model 3). The Cox proportional hazards assumption was met for all variables of interest. Due
to the small sample size, associations by tumor histology or specific race were not evaluated.
All statistical analyses were performed in SAS version 9.4 (SAS Institute, Cary, NC).
Results
Table 1 presents the baseline characteristics of this cohort of MEC smokers (n = 2,309) and the
characteristics for the 92 incident lung cancer cases. Among the eligible population there was a
CYP2A6 activity associated with lung cancer
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greater proportion of Japanese Americans (31%) and women (54%) than among cases. The
median age at urine collection was 63 years. As expected, those who developed lung cancer
during follow-up had characteristics that correlated with an increase in lung cancer risk [23].
These participants were slightly older at the time of urine collection and reported smoking
more CPD and for a longer duration. Also, those who became cases had higher levels of TNE
(33.5 vs. 32.4 nmol/ml) and CYP2A6 activity (3.8 vs. 3.3). As expected from our previous study
[7], higher CYP2A6 activity was associated with higher TNE even after adjusting for the covar-
iates in Model 2 (age at urine collection, sex, race/ethnicity, log-BMI, smoking duration
(years), log-urinary creatinine, and log-CPD) (partial correlation coefficient: 0.24, p<0.0001).
S1 Fig presents density distribution plots for TNE and the CYP2A6 activity ratio both without
and with log-transformation for the overall cohort and by lung cancer case-control status.
Both biomarkers are slightly skewed to the right. Those who developed lung cancer during
study follow-up presented with a slightly higher TNE and CYP2A6 activity levels than subjects
who did not become a case during the same period of time.
Table 2 presents the associations of known risk factors with lung cancer. Consistent with
previous findings in the entire MEC study [3], after accounting for age, sex, BMI, CPD and
smoking duration, when compared to whites, African Americans and Native Hawaiians had a
2-fold (95% CI: 1.02–3.91) and 1.79-fold (95% CI: 0.96–3.34) increased lung cancer risk,
respectively. CPD and smoking duration were both significantly associated with an increased
lung cancer risk (per unit increase in log-CPD, HR = 1.71; 95% CI: 1.22–2.39 and per year
increase in smoking duration, HR = 1.07; 95 CI: 1.03–1.11).
Table 1. Characteristics of MEC current smokers at time of urine collection and incident lung cancer cases identified in this group during follow-
up.
Eligible population Incident Lung cancer cases
(n = 2,309) (n = 92)
N % N %
Ethnicity/Race
African American 367 16% 18 20%
Native Hawaiian 331 14% 21 23%
White 445 19% 20 28%
Latino 457 20% 7 8%
Japanese American 709 31% 26 22%
Sex
Male 1067 46% 44 48%
Female 1242 54% 48 52%
Median (interquartile range) Median (interquartile range)
Age at time of urine collection (yrs) 63 (58–69) 66 (61–73)
Cigarettes per day (CPD) at time of urine collection 10 (6–20) 16 (10–20)
Body mass index (BMI) at time of urine collection (kg/m2) 25.6 (22.7–28.8) 24.4 (21.9–26.7)
Follow-up time (yrs) 9.5 (8.7–10.7) 6.6 (4.8–8.2)
Pack-years 23 (12–38) 35 (22–52)
Age at smoking initiation (yrs) 23 (19–29) 24 (21–26)
Smoking duration (yrs) at time of urine collection 41.5 (34.5–46.5) 46.5 (41.5–50.0)
Total nicotine equivalents (TNE) 32.4 (19.6–53.6) 33.5 (23.9–58.3)
CYP2A6 activitya 3.3 (1.80–5.59) 3.8 (2.05–6.09)
a CYP2A6 activity is the urinary total 3-HCOT/cotinine ratio
https://doi.org/10.1371/journal.pone.0178435.t001
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We found that after adjusting for age, sex, race/ethnicity, BMI, urinary creatinine levels,
and smoking duration (Model 1), both TNE and CYP2A6 activity were associated with an
increase in lung cancer risk (HR per log-TNE increase = 1.83; 95% CI: 1.24–2.71 and HR per
log-CYP2A6 activity increase = 1.60; 95% CI: 1.20–2.14). With further adjustment for self-
reported smoking dose (Model 2), CPD, CYP2A6 activity remained associated with lung can-
cer risk (HR per unit increase in log-CYP2A6 activity = 1.52; 95% CI: 1.14–2.04), whereas, the
lung cancer association with TNE was only of borderline statistical significance (HR per log-
TNE increase = 1.53; 95% CI: 0.99–2.37) (Table 3, Model 2). When adjusting for CYP2A6
activity, a biomarker found to influence smoking dose [7, 8, 10], the association with TNE was
no longer statistically significant (lung cancer HR per unit increase in log-TNE = 1.30; 95% CI:
0.85–1.99). Alternatively, when further adjusting for TNE, log-CYP2A6 activity remained sig-
nificantly associated with lung cancer (HR per unit increase in log-CYP2A6 activity = 1.46;
95% CI: 1.08–1.98). Moreover, when Japanese Americans, a population with a high frequency
of the CYP2A6 null allele, 4, were removed from our analysis, the association for higher
CYP2A6 activity ratio with lung cancer risk was still statistically significant in the remaining
four racial/ethnic groups (HR = 1.53; 95% CI: 1.03–2.26).
Discussion
This is the first study showing that a biochemical marker of nicotine metabolism is associated
with lung cancer risk. We found that even after accounting for both self-reported smoking his-
tory (CPD and duration) and internal smoking dose (TNE), and other potential confounders,
a one natural log-unit increase in the CYP2A6 enzymatic activity ratio (urinary total 3-HCOT/
Table 2. Associations of various characteristics at time of urine collection with lung cancer incidence
(n = 92 cases).
HRa (95% CI)a p-value
Female vs. Male 1.01 (0.65–1.55) 0.979
African American vs. White 2.00 (1.02–3.91) 0.043
Native Hawaiian vs. White 1.79 (0.96–3.34) 0.067
Latino vs. White 0.50 (0.20–1.21) 0.123
Japanese American vs. White 0.88 (0.49–1.59) 0.672
Body mass index (BMI) (natural log, kg/m2) 0.30 (0.10–0.95) 0.040
Cigarettes per day (CPD) (natural log) 1.71 (1.22–2.39) 0.002
Smoking duration (years) 1.07 (1.03–1.11) <0.0001
a Hazard ratio from Cox regression, adjusted for age, sex, race/ethnicity, log-BMI, log-CPD and smoking
duration
https://doi.org/10.1371/journal.pone.0178435.t002
Table 3. Associations of biomarkers of nicotine uptake (TNE) and nicotine metabolism (CYP2A6 activity) with lung cancer incidence (92 cases).
Model 1a Model 2b Model 3c
HR (95% CI) p HR (95% CI) p HR (95% CI) p
Log-TNE (nmol/ml) 1.83 (1.24–2.71) 0.002 1.53 (0.99–2.37) 0.06 1.30 (0.85–1.99) 0.22
Log-CYP2A6 activityd 1.60 (1.20–2.14) 0.002 1.52 (1.14–2.04) 0.005 1.46 (1.08–1.98) 0.015
a Model 1 includes age at urine collection, sex, race/ethnicity, log-BMI, smoking duration (years), and log-urinary creatinine.
b Model 2 further includes log-CPD
c Model 3 further includes log TNE or log-CYP2A6 activity
d CYP2A6 activity is the urinary total 3-HCOT/cotinine ratio
https://doi.org/10.1371/journal.pone.0178435.t003
CYP2A6 activity associated with lung cancer
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cotinine) was associated with a statistically significant 46% increased lung cancer risk. This
result suggests that CYP2A6 activity may capture information about risk beyond that provided
by smoking history.
In most smokers, at least 75% of the metabolism of nicotine occurs via CYP2A6-mediated
C-oxidation [5, 6]. Prior studies have shown that CYP2A6 activity, measured by various
metabolite ratios (e.g. total 3-HCOT/total cotinine, 3-HCOT/cotinine, and total 3-HCOT/
cotinine) modifies internal smoking dose [7, 8, 10]. Individuals with low nicotine metabolism
were found to smoke less intensively in order to achieve the same internal dose of nicotine, the
addictive component in tobacco, compared to individuals who metabolize nicotine more rap-
idly [7, 8, 10]. In an earlier analysis examining the inter-relationships of the biomarkers under
study in our MEC smokers population, we showed that CYP2A6 activity and genetic variants
of CYP2A6 activity were positively associated with TNE and that this association was consis-
tently observed in all five racial/ethnic groups [9]. In the present lung cancer analysis, when
CYP2A6 activity was adjusted for, TNE was no longer associated with risk, suggesting that the
enzymatic activity ratio more accurately captures a smoker’s long-term tobacco carcinogens
exposure than does TNE, which only reflects short-term exposure. Additionally, lower
CYP2A6 activity may result in a reduction in the activation of the lung carcinogen NNK by
CYP2A6. CYP2A6 activity has been has been correlated with lower bioactivation, which would
lead to lower levels of NNK-related DNA adducts and a potential decrease in tumor induction
[24].
Previous studies have investigated the association of functional variants in the CYP2A6
gene with lung cancer risk. Some studies reported that, consistent with our findings, low
CYP2A6 activity variants were associated with a reduced risk of lung cancer [14–16], possibly
only in smokers [18]. However, other studies have shown that low activity variants were either
not associated or positively associated with risk [12, 13, 17]. These inconsistencies may be the
result of small sample sizes and difficulty in genotyping this region due to the high sequence
homology (>85%) that exists between CYP2A6 and CYP2A7, as well as the marked racial/eth-
nic differences in frequency for the functional variants[25].
In an earlier report, using a genome-wide association study approach in two independent
studies, we showed that the top six CYP2A6 variants associated with lung cancer risk
(n = 13,479 cases and 43,218 controls) were also associated with CYP2A6 activity [19]. Consis-
tent with our findings, a recent publication by Yuan et al. [11] found that candidate genotyping
of four known poor metabolizing variants were associated with lower TNE levels and a 26%
decreased risk of lung cancer. However, this study was comprised of Chinese, a population
with a relatively high frequency of the CYP2A6 deletion (4) and the association of lung cancer
risk with the CYP2A6 genotype was no longer statistically significant when adjusted for TNE.
Whereas, in the present prospective study of five racial/ethnic groups (with a range of frequen-
cies for CYP2A6 variant alleles), we observed a significant association for CYP2A6 activity
with lung cancer risk, even after adjusting for TNE. Indeed, when Japanese Americans, a
group with a >35% frequency of carrying at least one copy of the CYP2A6 gene deletion (4)
[9], were removed from our analysis, the association for higher CYP2A6 activity with lung can-
cer was statistically significant in the remaining four racial/ethnic groups. These results suggest
that the CYP2A6 activity biomarker (urinary total 3-HCOT/cotinine) may capture the net
effect of various CYP2A6 variants, which individually may each have only a modest effect on
nicotine metabolism, and that of possible inducers that are typically not measured in genetic
association studies.
The present study’s limitations include the modest number of lung cancer cases and inabil-
ity to investigate risk by tumor cell-type or race/ethnicity. Replication in a prospective study
with a larger number of lung cancer cases is warranted. The study strengths include the
CYP2A6 activity associated with lung cancer
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prospective design, the racial/ethnic diversity of our sample, our ability to adjust for confound-
ers, and our comprehensive, biomarker-based measurements of the metabolic phenotype and
exposure of interest.
In conclusion, this study suggests that a urinary marker of nicotine metabolism is associ-
ated with incidence of lung cancer in smokers, even after taking into account self-reported
smoking history or a short-term biomarker of dose. Thus, measuring CYP2A6 activity may
improve lung cancer risk prediction in smokers. Additional prospective analyses with a larger
sample size are warranted to confirm these findings.
Supporting information
S1 Fig. Density distribution plots for TNE and the CYP2A6 activity ratio both without and
with log-transformation for the MEC smokers and by the participants’ lung cancer case-
control status. Figure A presents the density distribution plot for TNE without log-transfor-
mation; figure B presents the density distribution plot for TNE with log-transformation; figure
C presents the density distribution plot for CYP2A6 without log-transformation; and figure D
presents the density distribution plot for CYP2A6 with log-transformation.
(PDF)
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